India’s pharmaceutical sector has witnessed remarkable growth over the past decade, driven by government initiatives focused on affordable healthcare, domestic manufacturing, and innovation. From expanding access to low-cost medicines through the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) to strengthening pharmaceutical production through the Production Linked Incentive (PLI) Scheme, India is steadily advancing toward becoming a global healthcare leader while ensuring better healthcare access for its citizens.
One of the most significant achievements in recent years has been the rapid expansion of the Jan Aushadhi network. According to the Ministry of Chemicals and Fertilizers, the number of Jan Aushadhi Kendras has increased from just 84 functional stores in 2014 to over 19,200 outlets in 2026. This extraordinary growth reflects the government’s commitment to making quality medicines affordable and accessible across the country.
Expanding Affordable Healthcare
The Jan Aushadhi initiative was launched to provide quality generic medicines at significantly lower prices compared to branded drugs. High medicine costs often force patients to compromise on treatment, especially those suffering from chronic illnesses that require long-term medication. By offering affordable alternatives, Jan Aushadhi Kendras have helped millions of people access essential medicines without placing a heavy burden on their finances.
The impact of the scheme has been particularly noticeable in rural and underserved areas, where healthcare infrastructure is often limited. The availability of low-cost medicines through a widespread retail network has improved treatment accessibility and encouraged greater healthcare awareness among the population.
Transforming Healthcare in the North East
The North Eastern region of India has emerged as one of the biggest beneficiaries of the Jan Aushadhi expansion. In 2014, only a single Jan Aushadhi Kendra was operational in the region. Today, the number has increased to 417 outlets, ensuring that affordable medicines reach even remote and geographically challenging locations.
This expansion has helped bridge healthcare disparities and improved access to medicines for communities that previously had limited options. The success of the scheme demonstrates how targeted healthcare initiatives can significantly improve public health outcomes in underserved regions.
Massive Savings for Citizens
One of the strongest indicators of the scheme’s success is the financial relief it has provided to patients. Government estimates suggest that citizens have collectively saved more than ₹40,000 crore on healthcare expenses through purchases made at Jan Aushadhi Kendras.
These savings are particularly important for patients managing chronic diseases such as diabetes, hypertension, cardiovascular disorders, and respiratory illnesses. Since treatment for such conditions often continues for years, lower medicine costs help reduce financial stress and improve adherence to prescribed therapies.
Strengthening Pharmaceutical Manufacturing
Alongside improving medicine accessibility, India has focused on strengthening domestic pharmaceutical manufacturing through the Production Linked Incentive (PLI) Scheme. The initiative aims to encourage investment, boost production capacity, reduce import dependence, and promote the manufacturing of high-value pharmaceutical products within the country.
The results have been impressive. Since its launch, the pharmaceutical PLI scheme has attracted investments exceeding ₹42,000 crore and generated pharmaceutical sales worth more than ₹3.4 lakh crore. These achievements highlight the growing strength of India’s pharmaceutical industry and its ability to compete globally.
The scheme has also encouraged the production of complex generics, specialty medicines, and biopharmaceutical products, helping Indian companies move beyond traditional generic manufacturing and enter higher-value segments of the global pharmaceutical market.
Creating Employment Opportunities
The growth of the pharmaceutical industry has translated into substantial employment generation. According to official estimates, the PLI scheme has created job opportunities for more than 1.13 lakh people across various sectors of the pharmaceutical ecosystem.
From manufacturing and quality control to research, regulatory affairs, and supply chain management, the expanding industry is providing career opportunities for pharmacists, scientists, engineers, and healthcare professionals. This growth is expected to continue as investments increase and production capacities expand further.
Growth of the Medical Devices Sector
India’s healthcare transformation is not limited to pharmaceuticals alone. The country’s medical devices sector has also witnessed significant progress under the government’s PLI program. Investments of more than ₹1,100 crore have resulted in cumulative sales of nearly ₹29,400 crore, strengthening domestic manufacturing capabilities and reducing dependence on imported medical equipment.
To support this growth, Medical Device Parks are being established in states such as Uttar Pradesh, Tamil Nadu, and Madhya Pradesh. These parks provide shared infrastructure, testing facilities, and manufacturing support, helping companies reduce costs and improve competitiveness.
Conclusion
The expansion of the Jan Aushadhi network to more than 19,200 stores marks a major milestone in India’s journey toward affordable and accessible healthcare. Combined with the success of the pharmaceutical and medical device PLI schemes, it demonstrates the country’s commitment to improving public health while strengthening domestic manufacturing.
Recommended Products
